<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="159785">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01941394</url>
  </required_header>
  <id_info>
    <org_study_id>NRCH-MSC</org_study_id>
    <nct_id>NCT01941394</nct_id>
  </id_info>
  <brief_title>Mesenchymal Stem Cells Infusion for aGVHD Prophylaxis Transplantation</brief_title>
  <official_title>Pilot Study for Safety and Effectiveness Assessment of Bone Marrow Mesenchymal Stem Cell Infusion for Acute Graft-versus-host Disease Prophylaxis and Treatment After Allogenic Bone Marrow Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Research Center for Hematology, Russia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Research Center for Hematology, Russia</source>
  <oversight_info>
    <authority>Russia: Ministry of Health of the Russian Federation</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Infusion of Mesenchymal Stem Cell (MSC) at day of recovery after bone marrow transplant
      (BMT) for patients with AL, AA and MM for acute Graft-versus-host Disease (GVHD) prophylaxis
      and treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Infusion of mesenchymal stem cells at day of recovery after BMT for patients with AL, AA and
      MM for acute GVHD prophylaxis and treatment. Infusion at dose 1 cells mln/kg  at day of
      white blood cells recovery.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2007</start_date>
  <completion_date type="Anticipated">October 2014</completion_date>
  <primary_completion_date type="Anticipated">October 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>GVHD</measure>
    <time_frame>Every 30 day for 1 year after BMT</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>Every 30 day for 1 year after BMT</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relapse-free survival</measure>
    <time_frame>Every 30 day for 1 year after BMT</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Infection rate</measure>
    <time_frame>Every 30 day for 1 year after BMT</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Graft-versus-host Disease</condition>
  <condition>Relapse</condition>
  <arm_group>
    <arm_group_label>With MSC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>infusion of Mesenchymal stem cells at dose 1 mln cells per kg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Without MSC</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Without MSC infusion</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Mesenchymal stem cells</intervention_name>
    <description>Mesenchymal stem cells infusion</description>
    <arm_group_label>With MSC</arm_group_label>
    <other_name>Mesenchymal stem cells infusion</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  allogenic BMT from related or unrelated donor

        Exclusion Criteria:

          -  Severe infection

          -  Relapse

          -  admission to ICU

          -  refusal of research

          -  patients with graft failure
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elena Parovichnikova, Prof MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Research Center for Hematology</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Elena Parovichnikova, Prof MD PhD</last_name>
    <phone>+79161252623</phone>
    <email>elenap@blood.ru</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Larisa Kuzmina, MD PhD</last_name>
    <phone>+79161487131</phone>
    <email>kuzlara@rambler.ru</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>BMT department</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elena Parovichnikova, Prof MD PhD</last_name>
      <phone>+79161487131</phone>
      <email>kuzlara@rambler.ru</email>
    </contact>
    <investigator>
      <last_name>Elena Parovichnikova</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <results_reference>
    <citation>Kuzmina LA, Petinati NA, Parovichnikova EN, Lubimova LS, Gribanova EO, Gaponova TV, Shipounova IN, Zhironkina OA, Bigildeev AE, Svinareva DA, Drize NJ, Savchenko VG. Multipotent Mesenchymal Stromal Cells for the Prophylaxis of Acute Graft-versus-Host Disease-A Phase II Study. Stem Cells Int. 2012;2012:968213. doi: 10.1155/2012/968213. Epub 2011 Dec 25.</citation>
    <PMID>22242033</PMID>
  </results_reference>
  <verification_date>September 2013</verification_date>
  <lastchanged_date>September 12, 2013</lastchanged_date>
  <firstreceived_date>August 30, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>National Research Center for Hematology, Russia</investigator_affiliation>
    <investigator_full_name>Elena N.Parovichnikova</investigator_full_name>
    <investigator_title>Head of BMT department</investigator_title>
  </responsible_party>
  <keyword>GVHD</keyword>
  <keyword>Relapse</keyword>
  <keyword>Overall Survival</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Graft vs Host Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
